Fundraising Fox

Maria Fardis

Investor

Venture Partner at Frazier Life Sciences

Palo Alto

About

Maria Fardis joined Frazier Life Sciences as a Venture Partner in 2021 and has more than 20 years of scientific and management experience across public and private companies. She currently serves as CEO of Lassen Therapeutics and previously held leadership roles including President and CEO of Iovance Biotherapeutics, COO of Acerta Pharma, and senior positions at Pharmacyclics and Gilead Sciences. She holds a Ph.D. in Organic Chemistry from UC Berkeley, a B.S. in chemistry from the University of Illinois, Urbana-Champaign, and an M.B.A. from Golden Gate University.

Invests in

Biotech

Experience

  1. AirNexis Therapeutics Inc.Chief Executive Officercurrent2026 β€” present
  2. CRISPR TherapeuticsMember Board Of Directorscurrent2022 β€” presentCambridge, Massachusetts, United States
  3. Obsidian TherapeuticsChair Of The Board Of Directorscurrent2021 β€” presentCambridge, Massachusetts, United States
  4. Frazier Healthcare PartnersVenture Partnercurrent2021 β€” presentSan Francisco Bay Area
  5. Quanta TherapeuticsMember Board of Directorscurrent2021 β€” presentSouth San Francisco, California, United States
  6. Lassen TherapeuticsChief Executive Officer2023 β€” 2026San Diego, California, United States
  7. Kartos TherapeuticsMember Board Of Directors2018 β€” 2021Redwood Shores
  8. Iovance Biotherapeutics, Inc.President & Chief Executive Officer2016 β€” 2021San Francisco Bay Area
  9. Acerta Pharma B.V.Chief Operating Officer2015 β€” 2016San Carlos, CA
  10. PharmacyclicsChief of Oncology Operations and Alliances2013 β€” 2014Sunnyvale, CA
  11. PharmacyclicsEVP of Operations and Alliances2012 β€” 2013
  12. PharmacyclicsVP, Alliances and Global Project Management2011 β€” 2012Sunnyvale, CA
  13. PharmacyclicsSenior Director, Global Project Management2011Sunnyvale, CA
  14. Gilead SciencesAssociate Director, Project and Portfolio Management2010 β€” 2011
  15. Gilead SciencesSenior Manager, Project and Portfolio Management2006 β€” 2010
  16. Gilead SciencesSenior Scientist, Medicinal Chemistry2005 β€” 2006
  17. Gilead SciencesScientist II, Medicinal Chemistry2004 β€” 2005
  18. Gilead SciencesScientist, Medicinal Chemistry2001 β€” 2004
  19. Intrabiotics PharmaceuticalsScientist, Medicinal Chemistry2001
  20. Kosan Biosciences acquired by Brisol-Myers SquibbScientist, Medicinal Chemistry1998 β€” 2000

Education

  1. Golden Gate UniversityMBA, Management2004 β€” 2007
  2. University of California, BerkeleyPh.D., Organic Chemistry1993 β€” 1998
  3. University of Illinois Urbana-ChampaignB.S., Organic Chemistry1989 β€” 1992

Skills & more

Biotechnology99Clinical Development99Clinical Trials86Clinical Research46Project Management37Oncology99Lifesciences18GMP19Cancer30Drug Discovery23Medicinal Chemistry12GCP23
+12 moreRegulatory AffairsDrug DevelopmentCross-functional Team LeadershipBiopharmaceuticalsFDAFormulationInfectious DiseasesRegulatory SubmissionsCTMSINDPharmaceutical IndustryCRO

From Maria's professional profile.

Same school

Shared employers

Deals Β· 1

Quanta Therapeutics, Inc.Board seat

via Frazier Life Sciences Β· filed Jun 2026 Β· $89.1M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at Frazier Life Sciences